Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.810
-0.180 (-9.05%)
At close: Jun 27, 2025, 4:00 PM
1.840
+0.030 (1.66%)
After-hours: Jun 27, 2025, 6:36 PM EDT

Company Description

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States.

It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair.

Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California.

Biomea Fusion, Inc.
Biomea Fusion logo
Country United States
Founded 2017
IPO Date Apr 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 106
CEO Michael J. Hitchcock

Contact Details

Address:
1599 Industrial Road
San Carlos, California 94070
United States
Phone 650 980 9099
Website biomeafusion.com

Stock Details

Ticker Symbol BMEA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001840439
CUSIP Number 09077A106
ISIN Number US09077A1060
SIC Code 2834

Key Executives

Name Position
Dr. Michael J. M. Hitchcock Ph.D. Interim Chief Executive Officer and Director
Ramses M. Erdtmann Co-Founder, President, Chief Operating Officer and Director
Heow Tan Chief Technology and Quality Officer
Naomi Cretcher Chief People Officer
Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Chemistry
Dr. Stephan Morris M.D. Chief Development Officer
Ravi Upasani Ph.D. Executive Vice President of Intellectual Property
Dr. Juan Pablo Frias M.D. Chief Medical Officer
Caroline Perez- Dupont J.D. Senior Vice President of Contracts

Latest SEC Filings

Date Type Title
Jun 25, 2025 SCHEDULE 13G Filing
Jun 20, 2025 8-K Current Report
Jun 18, 2025 8-K Current Report
Jun 18, 2025 424B5 Filing
Jun 17, 2025 424B5 Filing
Jun 17, 2025 8-K Current Report
Jun 13, 2025 8-K Current Report
May 5, 2025 10-Q Quarterly Report
May 5, 2025 8-K Current Report
Apr 28, 2025 ARS Filing